At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Ixazomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Ixazomib, Lenalidomide, and 1 other intervention for Smoldering Multiple Myeloma. Completed, enrolled 61 participants across 1 site.
Detailed Summary
This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoldering Multiple Myeloma
CountriesUnited States
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionJan 2025
TodayJul 2026
First PostedSep 27, 2016
Enrollment StartOct 1, 2016
Primary CompletionJan 8, 2025
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 9.8 years ago
Interventions
Ixazomibdrug
Oral, proteasome inhibitor
Lenalidomidedrug
Oral, immunomodulatory agent
Dexamethasonedrug
Oral, steroid